Vanguard Portfolio Management
PVLA

Vanguard Portfolio Management’s Palvella Therapeutics PVLA Stock Holding History

Vanguard Portfolio Management’s Portfolio PVLA Stock Details PVLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.7M Buy
128,962
+38,104
+42% +$4.62M ﹤0.01% 2005
2026
Q1 		$11.3M Buy
+90,858
New +$9.48M ﹤0.01% 2080

Other funds holding PVLA

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Vanguard Portfolio Management's PVLA Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Palvella Therapeutics (PVLA) stake by 42% in Q2 2026, buying an estimated $4.62M and bringing the position to 128,962 shares worth $19.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2005.

Vanguard Portfolio Management first reported a position in PVLA in Q1 2026 and has held it in 2 quarters since. 196 funds tracked by Wall St. Rank hold PVLA as of Q2 2026.

  • Vanguard Portfolio Management held 128,962 shares of Palvella Therapeutics worth $19.7M as of Q2 2026.
  • Vanguard Portfolio Management bought 38,104 Palvella Therapeutics shares in Q2 2026, an estimated $4.62M.
  • Palvella Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2005 holding.
  • Vanguard Portfolio Management first reported a position in Palvella Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 196 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.